MBX Biosciences, Inc. Common Stock
MBXStock
$58.32+352.80%52W
Market Cap$2.89B
P/E—
Div yield—
Beta1.55
Price Chart
Favorite Metrics
Price vs S&P 500 (26W)76.95%
Price vs S&P 500 (4W)50.75%
VGM Score82.44
Market Capitalization$2.89B
Earnings Surprise History
Q1 26-0.51est. -0.59
Analyst Recommendations
Apr 2026
May 2026
Jun 2026
Jul 2026
4.13
4.13
4.13
4.13
Industry Peers — Pharmaceuticals(563)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
MBXMBX Biosciences, Inc. Common Stock | — | — | A | $58.32 |
| LLYEli Lilly & Co. | D | B | B | $1169.17 |
| JNJJohnson & Johnson | D | C | B | $249.97 |
| ABBVABBVIE INC. | D | C | B | $254.39 |
| MRKMerck & Co., Inc. | C | C | B | $127.63 |
| NVSNovartis AG | C | C | C | $152.73 |
| NVONovo-Nordisk A/S | C | B | C | $51.48 |
| AZNAstraZeneca PLC | C | B | C | $169.29 |
| ABTAbbott Laboratories | C | C | D | $98.83 |
| PFEPfizer Inc. | B | C | C | $25.14 |
| VRTXVertex Pharmaceuticals Inc | D | C | C | $486.03 |
About
MBX Biosciences is a clinical-stage biopharmaceutical company developing precision peptide therapies for endocrine and metabolic disorders. Its proprietary PEP platform optimizes pharmaceutical properties including extended duration, consistent drug exposure, and reduced dosing frequency compared to conventional peptides. The company's pipeline includes three candidates: MBX 2109, MBX 1416, and MBX 4291.